Title: Baricitinib in Patients with Refractory Rheumatoid Arthritis.
Journal: The New England journal of medicine 20160331
Title: Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.
Journal: EBioMedicine 20150401
Title: Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.
Journal: Nature medicine 20140901
Title: Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.
Journal: Journal of medicinal chemistry 20140626
Title: Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
Journal: Clinical and experimental immunology 20131201
Title: Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
Journal: Journal of immunology (Baltimore, Md. : 1950) 20100501
1189746-27-7 | 2-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole | AA003A6V | MFCD11109436
928783-29-3 | 4-[5-(3,5-Dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[(methoxyamino)methylene]-2-methylbenzamide | AA003AKW | MFCD31692349